ATE477339T1 - Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung - Google Patents

Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung

Info

Publication number
ATE477339T1
ATE477339T1 AT06742440T AT06742440T ATE477339T1 AT E477339 T1 ATE477339 T1 AT E477339T1 AT 06742440 T AT06742440 T AT 06742440T AT 06742440 T AT06742440 T AT 06742440T AT E477339 T1 ATE477339 T1 AT E477339T1
Authority
AT
Austria
Prior art keywords
compositions
markers
treatment
outcome
predicting
Prior art date
Application number
AT06742440T
Other languages
English (en)
Inventor
Kirsten Nielsen
Bent Eilertsen
Tim Poulsen
Henning Mouridsen
Original Assignee
Dako Denmark As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dako Denmark As filed Critical Dako Denmark As
Application granted granted Critical
Publication of ATE477339T1 publication Critical patent/ATE477339T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Processing Of Solid Wastes (AREA)
AT06742440T 2005-05-31 2006-05-30 Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung ATE477339T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68607005P 2005-05-31 2005-05-31
PCT/DK2006/000300 WO2006128463A2 (en) 2005-05-31 2006-05-30 Compositions and methods for predicting outcome of treatment

Publications (1)

Publication Number Publication Date
ATE477339T1 true ATE477339T1 (de) 2010-08-15

Family

ID=35809661

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06742440T ATE477339T1 (de) 2005-05-31 2006-05-30 Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung

Country Status (6)

Country Link
US (1) US8679746B2 (de)
EP (1) EP1885878B1 (de)
AT (1) ATE477339T1 (de)
DE (1) DE602006016106D1 (de)
ES (1) ES2350648T3 (de)
WO (1) WO2006128463A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110318732A1 (en) * 2008-05-28 2011-12-29 Singer Robert H Prediction of chemotherapeutic response via single-cell profiling of transcription site activation
EP3216874A1 (de) 2008-09-05 2017-09-13 TOMA Biosciences, Inc. Verfahren zum stratifizieren und annotieren der behandlungsoptionen eines krebsmedikaments
AU2010253978B2 (en) * 2009-05-29 2014-12-11 Ventana Medical Systems, Inc. Methods of scoring gene copy number in a biological sample using in situ hybridization
KR20130113447A (ko) 2010-09-24 2013-10-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 고정된 프라이머들을 이용하여 표적 dna의 직접적인 캡쳐, 증폭 및 서열화
US9556473B2 (en) * 2011-02-15 2017-01-31 Leica Biosystems Newcastle Ltd Methods for identifying nucleic acid sequences
US10839509B2 (en) 2015-07-10 2020-11-17 3Scan Inc. Spatial multiplexing of histological stains

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004004571T2 (de) 2003-08-28 2007-11-08 Roche Diagnostics Gmbh Abhängigkeit des symptomfreien Überlebens 5-FU behandelter Darmkrebspatienten vom Verhältnis der mRNA-Expressionshöhe aus Thymidinphosphorylase und Dihydropyrimidindehydrogenase

Also Published As

Publication number Publication date
US20090042187A1 (en) 2009-02-12
DE602006016106D1 (de) 2010-09-23
WO2006128463A2 (en) 2006-12-07
EP1885878B1 (de) 2010-08-11
ES2350648T3 (es) 2011-01-25
WO2006128463A3 (en) 2007-02-15
EP1885878A2 (de) 2008-02-13
US8679746B2 (en) 2014-03-25

Similar Documents

Publication Publication Date Title
ATE497496T1 (de) 2,4-pyridimediamon-derivate als hemmer von jak- kinasen zur behandlung von autoimmunerkrankungen
EA200870391A1 (ru) Тетрагидропирролопиримидиндионы и их применение в качестве ингибиторов эластазы нейтрофилов человека
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
MX2009006466A (es) Metodos de tratamiento de cancer con inhibidores del receptor del factor 1 de crecimiento similar a la insulina.
ZA200702322B (en) Compositions and methods for the diagnosis and treatment of tumor
EP2125855A4 (de) Verfahren und zusammensetzungen zur behandlung von krebs und anderen krankheiten
PH12014500053A1 (en) Proteasome inhibitors
NO20080361L (no) Preparater og fremgangsmater for diagnostiseringer og behandlinger av tumor
EA201001143A1 (ru) Активаторы прокаспаз "исполнителей" 3, 6 и 7
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
ZA200702973B (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2006113483A3 (en) Methods and compositions for treating or preventing cancer
WO2006015079A3 (en) Erm family binding agents and their use in diagnosis and treatment of proliferative conditions
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
ATE477339T1 (de) Zusammensetzungen und verfahren zur vorhersage des ausgangs einer behandlung
RS20060584A (en) Beta-carbolines useful for treating inflammatory disease
WO2008088860A3 (en) Polymorphisms in the egfr pathway as markers for cancer treatment
DE602004021435D1 (de) Injizierbare zusammensetzung zur behandlung von krebs
WO2007098047A3 (en) Methods and compositions for the treatment of parkinson's disease
EP1987165A4 (de) Gene mit einfluss auf die menschliche gedächtnisleistung
DE602005019770D1 (de) Medizinische zusammensetzung zur behandlung von krebs oder diabetes
EP1720410A4 (de) Zusammensetzungen und verfahren für die behandlung und klinische remission von schuppenflechte
IL185900A0 (en) Compositions and methods for the diagnosis and treatment of tumor
ATE522625T1 (de) Verfahren und zusammensetzungen zur diagnose und behandlung von lungenkrebs mittels pdgfra-, kit- oder kdg-gen als genmarker

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties